Morgan Stanley Maintains Equal-Weight On Pfizer, Maintains $38 Target As Firm Notes 'Prevnar 20-valent (20vPnC) infant Phase 2 readout for prevention of pneumococcal disease is expected soon; we and consensus assume it moves into Phase 3'